Ricarte-Filho et al. [22] reported recently that PDTC, FDG-PET positive tumours refractory to radioactive iodine treatment, harbour BRAF mutations in 39% of the samples, whereas non-refractory PDTC display a significantly lower frequency of BRAF mutations (12%) [22]. This evidence concerns the gene BRAF and neoplasm.